Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
On Thursday, Cantor Fitzgerald reiterated an Overweight rating on Bicara Therapeutics Inc (NASDAQ:BCAX) stock, despite the shares falling 17.4% over the past week. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $31 to $47. The firm’s analyst highlighted the potential of Bicara’s leading drug candidate, ficerafusp, in treating first-line head and neck cancer, noting its progress and future market prospects.
Ficerafusp, an EGFR x TGF-beta bispecific, is currently in a Phase 2/3 trial for the treatment of head and neck squamous cell carcinoma (HNSCC). The analyst expressed confidence in the drug’s competitive positioning within the market. With an InvestingPro Financial Health score of "Good" and more cash than debt on its balance sheet, Bicara appears well-positioned to advance its clinical programs. Additionally, upcoming Phase 1/2 data is set to be presented at the American Society of Clinical Oncology (ASCO) 2025 meeting.
The firm remains optimistic about the future of Bicara Therapeutics, citing ficerafusp as a "de-risked, late-stage candidate with blockbuster potential." The market for first-line HNSCC treatment is valued in the billions and is expected to expand over time. With a current market capitalization of $708 million and a strong current ratio of 36, the anticipation of a pivotal readout in early 2027 is projected to drive BCAX shares to outperform in the market. Get more insights and exclusive financial metrics with InvestingPro.
In other recent news, Bicara Therapeutics Inc. shared promising results from its Phase 1/1b trial involving a combination of ficerafusp alfa and pembrolizumab for treating squamous cell carcinoma of the anal canal (SCAC). The trial reported a confirmed overall response rate of 25.0% and a median progression-free survival of 2.9 months, with a 12-month progression-free survival rate of 40.7%. Safety data indicated a tolerable profile, with common adverse events including acneiform dermatitis and pruritus. Following these results, H.C. Wainwright raised its price target for Bicara to $45, maintaining a Buy rating, highlighting the potential of SCAC as a future revenue driver. Similarly, Stifel reiterated a Buy rating with a $47 target, noting the encouraging depth and durability of responses in the trial. Analysts are looking forward to additional data disclosures in 2025, which could serve as catalysts for the company. Bicara’s Chief Medical (TASE:BLWV) Officer expressed optimism about the combination therapy’s potential for improved outcomes compared to pembrolizumab monotherapy. The ongoing development of ficerafusp alfa in various solid tumor types is a focus for Bicara, with analysts suggesting that the company’s current market valuation presents an investment opportunity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.